XSpray Pharma AB (XSPRAY) - Total Liabilities

Latest as of March 2026: Skr167.03 Million SEK ≈ $17.98 Million USD

Based on the latest financial reports, XSpray Pharma AB (XSPRAY) has total liabilities worth Skr167.03 Million SEK (≈ $17.98 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore XSPRAY net asset momentum to track the company's year-over-year net asset growth rate.

XSpray Pharma AB - Total Liabilities Trend (2015–2025)

This chart illustrates how XSpray Pharma AB's total liabilities have evolved over time, based on quarterly financial data. See XSpray Pharma AB (XSPRAY) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

XSpray Pharma AB Competitors by Total Liabilities

The table below lists competitors of XSpray Pharma AB ranked by their total liabilities.

Company	Country	Total Liabilities
Tambun Indah Land Bhd KLSE:5191	Malaysia	RM97.03 Million
FM Global Logistics Holdings Bhd KLSE:7210	Malaysia	RM439.04 Million
Ten Ren Tea Co Ltd TW:1233	Taiwan	NT$843.20 Million
Her Chee Industrial Co Ltd TWO:8937	Taiwan	NT$1.93 Billion
Popular Vehicles and Services Limited NSE:PVSL	India	Rs17.55 Billion
Jung Shing Wire Co Ltd TW:1617	Taiwan	NT$1.14 Billion
Groupe Minoteries SA SW:GMI	Switzerland	CHF45.97 Million
Hanjin Heavy Ind & Const Holdings Co Ltd KO:003480	Korea	₩1.21 Trillion

Liability Composition Analysis (2015–2025)

This chart breaks down XSpray Pharma AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see XSpray Pharma AB market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.02	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.29	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.23	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how XSpray Pharma AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for XSpray Pharma AB (2015–2025)

The table below shows the annual total liabilities of XSpray Pharma AB from 2015 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr164.70 Million ≈ $17.72 Million	-4.94%
2024-12-31	Skr173.25 Million ≈ $18.64 Million	+141.12%
2023-12-31	Skr71.85 Million ≈ $7.73 Million	+144.30%
2022-12-31	Skr29.41 Million ≈ $3.17 Million	-5.59%
2021-12-31	Skr31.15 Million ≈ $3.35 Million	+37.13%
2020-12-31	Skr22.72 Million ≈ $2.44 Million	-15.73%
2019-12-31	Skr26.96 Million ≈ $2.90 Million	+150.32%
2018-12-31	Skr10.77 Million ≈ $1.16 Million	+87.17%
2017-12-31	Skr5.75 Million ≈ $619.17K	+6.78%
2016-12-31	Skr5.39 Million ≈ $579.83K	+100.45%
2015-12-31	Skr2.69 Million ≈ $289.27K	--

About XSpray Pharma AB

ST:XSPRAY Sweden Biotechnology

Market Cap

$82.56 Million

Skr767.20 Million SEK

Market Cap Rank

#19833 Global

#352 in Sweden

Share Price

Skr16.18

Change (1 day)

-4.15%

52-Week Range

Skr14.50 - Skr63.40

All Time High

Skr258.00